C4 THERAPEUTICS INC's ticker is CCCC and the CUSIP is 12529R107. A total of 114 filers reported holding C4 THERAPEUTICS INC in Q2 2024. The put-call ratio across all filers is 0.44 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2024 | $119,016 | +3968.9% | 25,761 | +7095.8% | 0.00% | – |
| Q1 2024 | $2,925 | -60.2% | 358 | -72.5% | 0.00% | – |
| Q4 2023 | $7,357 | +1084.7% | 1,302 | +289.8% | 0.00% | – |
| Q3 2023 | $621 | -27.4% | 334 | +7.4% | 0.00% | – |
| Q2 2023 | $855 | -96.4% | 311 | -95.8% | 0.00% | – |
| Q1 2023 | $23,509 | -56.5% | 7,487 | +20.6% | 0.00% | – |
| Q3 2022 | $54,000 | +1250.0% | 6,209 | +1136.9% | 0.00% | – |
| Q2 2022 | $4,000 | -99.1% | 502 | -97.3% | 0.00% | – |
| Q1 2022 | $456,000 | -54.6% | 18,784 | -39.8% | 0.00% | – |
| Q4 2021 | $1,005,000 | -20.8% | 31,228 | +10.1% | 0.00% | – |
| Q3 2021 | $1,269,000 | – | 28,376 | +80974.3% | 0.00% | – |
| Q2 2021 | $0 | -100.0% | 35 | -99.3% | 0.00% | – |
| Q1 2021 | $195,000 | -84.7% | 5,279 | -86.3% | 0.00% | – |
| Q4 2020 | $1,277,000 | – | 38,527 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Lynx1 Capital Management LP | 6,880,527 | $31,788,035 | 11.47% |
| Soleus Capital Management, L.P. | 4,051,996 | $18,720,222 | 1.65% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 1,442,841 | $6,665,925 | 1.57% |
| COMMODORE CAPITAL LP | 3,410,384 | $15,755,974 | 1.08% |
| TCG Crossover Management, LLC | 1,276,574 | $5,897,772 | 0.62% |
| Bain Capital Life Sciences Investors, LLC | 1,111,910 | $5,137,024 | 0.56% |
| RA Capital Management | 4,878,000 | $22,536,360 | 0.30% |
| Atom Investors LP | 332,620 | $1,536,704 | 0.15% |
| Orbimed Advisors | 1,513,058 | $6,990,328 | 0.14% |
| WASATCH ADVISORS LP | 4,847,150 | $22,393,833 | 0.12% |